What Does Semaglutide Do? Weight Loss & Diabetes Management

Last reviewed: May 28, 2026

Last updated: May 28, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone regulating appetite, blood sugar, and metabolic function. FDA-approved formulations include Wegovy for chronic weight management and Ozempic for type 2 diabetes; compounded versions offer additional access pathways with qualified provider oversight.

Understanding what semaglutide does—and how it may work differently for each person—is essential before starting treatment. PlexusDx emphasizes precision wellness: genetic factors, biomarkers, and individual metabolic patterns can inform whether semaglutide may align with your health goals and help your provider optimize your treatment plan.

How Semaglutide Works: The GLP-1 Mechanism in Action

Semaglutide binds to GLP-1 receptors in the brain, pancreas, and gastrointestinal tract. This action slows gastric emptying, increases feelings of fullness, and enhances insulin secretion when blood glucose rises. The result is reduced calorie intake and improved glycemic control without direct stimulation of pancreatic beta cells.

The GLP-1R gene variant rs6923761 influences how efficiently your cells respond to GLP-1 signaling. Individuals with certain alleles may experience variable baseline sensitivity to GLP-1 agonists, suggesting that genetic context can inform dose titration and formulation selection discussions with your provider.

Clinical Evidence: Weight Loss, Blood Sugar, and Cardiovascular Outcomes

Large randomized controlled trials demonstrate semaglutide's effectiveness. The STEP trials (Wegovy in weight management) showed 10–15% body weight reduction over 68 weeks. The SUSTAIN trials (Ozempic in type 2 diabetes) consistently reduced HbA1c by 1.5–2.0%. Cardiovascular benefit meta-analyses support its use in patients with obesity and concurrent cardiometabolic disease.

Clinical Outcome	Evidence Summary	Patient Relevance
Weight Loss (STEP Trials)	10–15% body weight reduction over 68 weeks	Sustained weight management when paired with lifestyle changes
Blood Sugar Control (SUSTAIN Trials)	HbA1c reduction of 1.5–2.0% in type 2 diabetes	Improved glycemic control with lower hypoglycemia risk
Cardiovascular Safety	Reduced major adverse cardiac events in high-risk cohorts	Cardioprotective effect independent of weight loss alone
Gastrointestinal Tolerability	Nausea, vomiting, constipation more common at higher doses	Slow dose escalation can mitigate side effects

Individual Variation: Why Response Differs Across Patients

Not all patients achieve identical weight loss or blood sugar improvement on semaglutide. Genetic polymorphisms in the GIPR (glucose-dependent insulinotropic polypeptide receptor) gene and FTO (fat mass and obesity-associated) gene influence baseline metabolic rate, appetite signaling, and fat distribution. Baseline BMI, age, insulin resistance, and concurrent medications also modulate response.

The MC4R rs17782313 variant is associated with monogenic obesity pathways and may predict differential semaglutide efficacy in specific populations. Measuring baseline markers—fasting glucose, insulin levels, inflammatory cytokines, lipid profiles—can help your provider contextualize expected outcomes and adjust expectations realistically.

Safety Considerations and Who Semaglutide May or May Not Suit

Semaglutide is contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Common side effects include nausea, vomiting, constipation, and diarrhea, typically transient with slow dose escalation. Pancreatitis, diabetic retinopathy worsening, and gallstone formation require monitoring. Dehydration risk increases in patients taking other medications affecting fluid balance.

Pregnancy, breastfeeding, and severe renal or hepatic disease warrant careful provider evaluation. Patients with history of gastroparesis, inflammatory bowel disease, or personal bariatric surgery need individualized assessment. A qualified healthcare provider should review your complete medical history, medications, and baseline labs before initiating any semaglutide formulation—whether branded or compounded.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines four key variants in GLP-1 and metabolic pathways—GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These variants may help provide context about your genetic predispositions in appetite regulation and metabolic processing. Results should be interpreted with your qualified healthcare provider to inform treatment discussions, not to predict exact medication response.

The Precision Peptide Genetic Test reveals predispositions in peptide-signaling pathways relevant to semaglutide efficacy. For example, specific FTO or MC4R variants correlate with baseline metabolic phenotypes that may influence how your body responds to GLP-1 agonism. This genetic context does not guarantee treatment success but can support a more nuanced conversation about realistic goals and dose optimization.

When combined with your clinical history, biomarkers, and provider assessment, genetic insights from the Precision Peptide test can help you and your healthcare team make more informed decisions about whether compounded semaglutide, oral semaglutide, or other GLP-1 formulations align with your metabolic profile and health objectives. Compounded semaglutide from licensed 503A pharmacies offers individualized dosing flexibility under your provider's supervision.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.